3Degrees Appoints Philippe Vedrenne as Chief Executive Officer, Effective May 1, 2025
22.4.2025 18:00:00 CEST | Business Wire | Press Release
3Degrees, a leading global climate solutions provider and certified B Corporation, is pleased to announce the appointment of Philippe Vedrenne as Chief Executive Officer (CEO), effective May 1, 2025. Vedrenne is moving into the role as 3Degrees’ current CEO and co-founder Steve McDougal steps away from leadership of the company. McDougal informed the Board of Directors last year that he would be retiring as CEO; he will maintain his involvement as a member of the Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422978066/en/
3Degrees Appoints Philippe Vedrenne as Chief Executive Officer, Effective May 1, 2025
Vedrenne brings over two decades of global energy market experience operating across multiple continents. Most recently, at Engie, he oversaw trading and retail activities in North and South America for electricity and gas. In this position, he led efforts to bring utility-scale renewable energy solutions to the corporate market by combining wind, solar, and battery asset classes.
Vedrenne began his career in Europe at Gaz de France where he played a foundational role in the creation of Gasely, the trading business unit that evolved into Engie Global Markets, where he later became CEO. While running Engie’s natural gas midstream activities in Europe, he renegotiated the company’s long-term supply contracts to align them with markets, contributed to ensure European security of supply, and helped establish natural gas reverse flows to Ukraine in the wake of the Maidan uprisings and 2014 Russian-Ukrainian war. Before moving to the U.S. in 2021, Vedrenne led two significant projects for Engie: the development of renewable power purchase agreement (PPA) activities in Europe, and the net zero carbon project that defines Engie’s decarbonization ambition and trajectory to carbon neutrality by 2045.
“We are thrilled to welcome Philippe Vedrenne as the next CEO of 3Degrees,” said Dan Kalafatas, 3Degrees’ co-founder and Chair of the Board. “Our global search focused on selecting a new leader with the expertise to drive the next chapters of 3Degrees’ growth. Philippe brings a rare combination of global leadership experience, track record of success, service-leader orientation, and passion for bringing innovative decarbonization solutions to the world. The 3Degrees Board also wants to express deep gratitude to Steve McDougal. In his tenure as CEO, Steve spearheaded the company’s transformation from a small, North American-focused renewable energy commodity company into a leading global climate solutions provider advising some of the largest companies in the world.”
“I could not be more excited to assume the CEO role and help accelerate 3Degrees’ growth and our clients’ climate impact,” said Vedrenne. “The entire team is incredibly strong, with deep market and functional expertise. I’m looking forward to helping fuel the company’s continued expansion in both current and new markets, and to using our unique combination of market participation and client-centric focus to innovate new products and solutions. I’m honored to be asked to join such an exemplary organization, enabling me to work on a challenge of great urgency to us all.”
McDougal added, “Co-founding 3Degrees with Dan Kalafatas, and subsequently leading the company as CEO for the last ten years, has been one of the greatest privileges of my life. I am incredibly proud of what the 3Degrees team has built together over nearly two decades. I look forward to supporting the bright future for 3Degrees in my role on its Board of Directors and feel confident Philippe will be an excellent steward of the company as it expands its impact globally for our clients, partners, suppliers, employees, and the climate.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250422978066/en/
Contacts
Rachel Fagan
512.791.2083
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom